Old Port Advisors Sells 53 Shares of Danaher Co. (NYSE:DHR)

Old Port Advisors decreased its holdings in Danaher Co. (NYSE:DHR) by 4.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,092 shares of the conglomerate’s stock after selling 53 shares during the period. Old Port Advisors’ holdings in Danaher were worth $273,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. ST Germain D J Co. Inc. increased its position in shares of Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the last quarter. Godsey & Gibb Inc. raised its position in Danaher by 3.0% in the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after acquiring an additional 42 shares during the period. Nicholas Hoffman & Company LLC. grew its position in shares of Danaher by 2.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after acquiring an additional 43 shares during the period. Los Angeles Capital Management LLC increased its stake in shares of Danaher by 1.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock worth $803,000 after purchasing an additional 43 shares during the last quarter. Finally, Berger Financial Group Inc grew its holdings in Danaher by 1.7% during the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after purchasing an additional 43 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 1.4 %

Shares of Danaher stock traded down $4.01 during trading on Friday, reaching $276.75. The company’s stock had a trading volume of 3,108,808 shares, compared to its average volume of 3,183,765. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The firm’s 50-day moving average is $256.29 and its two-hundred day moving average is $250.94. The company has a market cap of $199.87 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm earned $2.05 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend was Friday, June 28th. Danaher’s payout ratio is 18.31%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DHR shares. SVB Leerink upped their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Jefferies Financial Group began coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. Bank of America lifted their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Insider Transactions at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Danaher news, CEO Rainer Blair sold 19,085 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,174 shares of company stock worth $29,775,644. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.